Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Visualitza/Obre
Cita com:
hdl:2117/88230
Tipus de documentArticle
Data publicació2016-01-26
EditorBioMed Central
Condicions d'accésAccés obert
Llevat que s'hi indiqui el contrari, els
continguts d'aquesta obra estan subjectes a la llicència de Creative Commons
:
Reconeixement 4.0 Internacional
ProjecteBLUEPRINT - A BLUEPRINT of Haematopoietic Epigenomes (EC-FP7-282510)
EPINORC - Epigenetic Disruption of Non-Coding RNAs in Human Cancer (EC-FP7-268626)
EPINORC - Epigenetic Disruption of Non-Coding RNAs in Human Cancer (EC-FP7-268626)
Abstract
Background
One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized.
Results
Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis.
Conclusions
We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
CitacióHeyn, Holger [et al.]. Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer. "Genome Biology", 26 Gener 2016, vol. 17, núm. 11.
ISSN1474-760X
Col·leccions
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
Epigenomic analysis detects aberrant.pdf | 3,670Mb | Visualitza/Obre |